Medivir announces a phase II all-oral study of Simeprevir (TMC435) and VX-135 for the treatment of Hepatitis C to be conducted by Janssen and Vertex
- Companies to evaluate a two-drug combination of Medivir/Janssen’s investigational protease inhibitor simeprevir (TMC435) and Vertex’s investigational nucleotide analogue VX-135- Phase II proof-of-concept study to begin in early 2013 to evaluate safety, tolerability and viral cure rates of 12-week treatment regimen Stockholm, Sweden—Medivir AB (OMX: MVIR), announced today plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen’s protease inhibitor simeprevir and Vertex’s nucleotide analogue hepatitis